Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frazer A Tessema

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 21, 2018
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T TherapyFrazer A Tessema, Jonathan J Darrow
JAMA|August 5, 2024
The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell DiseaseEdward R Scheffer Cliff, Frazer A Tessema
JAMA|April 9, 2026
Skinny Labels at the Supreme Court-Generic Competition, Patent Inducement, and Affordable MedicinesS Sean Tu, Frazer A Tessema, Aaron S Kesselheim
JAMA Internal Medicine|September 8, 2020
US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer AcetateBenjamin N Rome, Frazer A Tessema, Aaron S Kesselheim
Journal of the Society for Cardiovascular Angiography & Interventions|May 11, 2026
Baroreflex Activation Therapy Invasive Hemodynamic "Reverse Ramp" TitrationFrazer A Tessema, Jonathan Grinstein, Daniel Burkhoff, et al.
Health Affairs (Project Hope)|May 1, 2023
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously EstimatedFrazer A Tessema, Rachel E Barenie, Jerry Avorn, et al.
Drug Discovery Today|October 4, 2020
Public funding for transformative drugs: the case of sofosbuvirRachel E Barenie, Jerry Avorn, Frazer A Tessema, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 27, 2022
High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular MedicineFrazer A Tessema, Ameet Sarpatwari, Leah Z Rand, et al.
JAMA Network Open|August 31, 2019
Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled AnalysisBishal Gyawali, Frazer A Tessema, Emily H Jung, et al.
Journal of General Internal Medicine|February 6, 2024
Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer PharmaciesHussain S Lalani, Frazer A Tessema, Aaron S Kesselheim, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 21, 2018
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T TherapyFrazer A Tessema, Jonathan J Darrow
JAMA|August 5, 2024
The Double-Edged Sword of Extremely High Prices for Gene Therapies in Sickle Cell DiseaseEdward R Scheffer Cliff, Frazer A Tessema
JAMA|April 9, 2026
Skinny Labels at the Supreme Court-Generic Competition, Patent Inducement, and Affordable MedicinesS Sean Tu, Frazer A Tessema, Aaron S Kesselheim
JAMA Internal Medicine|September 8, 2020
US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer AcetateBenjamin N Rome, Frazer A Tessema, Aaron S Kesselheim
Journal of the Society for Cardiovascular Angiography & Interventions|May 11, 2026
Baroreflex Activation Therapy Invasive Hemodynamic "Reverse Ramp" TitrationFrazer A Tessema, Jonathan Grinstein, Daniel Burkhoff, et al.
Health Affairs (Project Hope)|May 1, 2023
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously EstimatedFrazer A Tessema, Rachel E Barenie, Jerry Avorn, et al.
Drug Discovery Today|October 4, 2020
Public funding for transformative drugs: the case of sofosbuvirRachel E Barenie, Jerry Avorn, Frazer A Tessema, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 27, 2022
High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular MedicineFrazer A Tessema, Ameet Sarpatwari, Leah Z Rand, et al.
JAMA Network Open|August 31, 2019
Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled AnalysisBishal Gyawali, Frazer A Tessema, Emily H Jung, et al.
Journal of General Internal Medicine|February 6, 2024
Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer PharmaciesHussain S Lalani, Frazer A Tessema, Aaron S Kesselheim, et al.
Pageof 3